Mixed connective tissue disease: To be or not to be?

Arthritis and Rheumatism

Volumn 41, Issue 5, 1998, Pages 768-777

  Smolen, Josef S ^a,b   Steiner, Günter ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; DISEASE ASSOCIATION; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; MIXED CONNECTIVE TISSUE DISEASE; RIBONUCLEOPROTEINS; SEROLOGIC TESTS;

EID: 0031957166     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199805)41:5<768::AID-ART3>3.0.CO;2-Z     Document Type: Review

References (100)

1. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen. Am J Med 1972;52:148-59.
2. Kasukawa R, Sharp GC, editors. Mixed connective tissue diseases and anti-nuclear antibodies. Amsterdam: Elsevier; 1987.
3. Sharp GC, Irvin WS, May CM, Holman HR, McDuffie FC, Hess EV, et al. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective tissue disease, systemic lupus erythematosus and other rheumatic diseases. N Engl J Med 1976;295:1149-54.
4. Lerner MR, Steitz JA. Antibodies to small nuclear RNAs complexed with proteins are produced by patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A 1979;76:5495-9.
5. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989;52:148-51.
6. Nimelstein SH, Brody ST, McShane D, Holman HR. Mixed connective tissue disease: a subsequent evaluation of the original 25 patients. Medicine (Baltimore) 1980;59:239-48.
7. Black C, Isenberg D. Mixed connective tissue disease - good bye to all that. Br J Rheumatol 1993;32:348-9.
8. Van den Hoogen FH, Spronk PE, Boerbooms AM, Bootsma H, de Rooij DJ, Kallenberg CGJ, et al. Long-term follow-up of 46 patients with anti-(U1)snRNP antibodies. Br J Rheumatol 1994; 33:1117-20.
9. Bennett RM. Mixed connective tissue disease and other overlap syndromes. In: Kelley WN, Harris ED Jr, Ruddy SH, Sledge CB, editors. Textbook of Rheumatology. 5th ed. Philadelphia: WB Saunders; 1997. p. 1065-78.
10. Kitridou R, Akmal M, Turkel SB, Ehresmann GR, Quismorio FP, Massry SG. Renal involvement in mixed connective tissue disease: a longitudinal clinicopathologic study. Semin Arthritis Rheum 1986;16:135-45.
11. LeRoy EC, Maricq HR, Kahaleh MB. Undifferentiated connective tissue syndromes. Arthritis Rheum 1980;23:341-3.
12. Cervera R, Khamashta MA, Hughes GRV. 'Overlap' syndromes. Ann Rheum Dis 1990;49:947-8.
13. Lundberg I, Hedfors E. Clinical course of patients with anti-RNP antibodies: a prospective study of 32 patients. J Rheumatol 1991;18:1511-9.
14. Hameenkorpi R, Ruuska P, Forsberg S, Tiilikainen R, Makitalo R, Hakala M. More evidence of distinctive features of mixed connective tissue disease. Scand J Rheumatol 1993;22:63-8.
15. Bennett R, O'Connell D. Mixed connective tissue disease: a clinicopathological study of 20 cases. Semin Arthritis Rheum 1980;10:15-52.
16. Kahn M-F. Mixed connective tissue dispute. Lupus 1995;4:258.
17. Klemperer P, Pollack AP, Baehr G. Diffuse collagen disease: acute disseminated lupus erythematosus and diffuse scleroderma. JAMA 1942;119:331-2.
18. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
19. Smolen JS. Clinical and serologic features: incidence and diagnostic approach. In: Smolen JS, Zielinski CC, editors. Systemic lupus erythematosus. Berlin: Springer Verlag; 1987. p. 170-96.
20. Fries J, Holman H. Systemic lupus erythematosus: a clinical analysis. Philadelphia: WB Saunders; 1975.
21. Fessel WJ. ANA-negative systemic lupus erythematosus. Am J Med 1978;64:80-6.
22. Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 1979;115:1409-15.
23. Boey ML, Colaco CB, Gharavi AE, Elkon KB, Loizou S, Hughes GRV. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. BMJ 1983;287:1021-3.
24. Isenberg DA, Steiner G, Smolen JS. Clinical utility and serological connections of anti-RA33 antibodies in systemic lupus erythematosus. J Rheumatol 1994;21:1260-3.
25. Tsokos GC, Moutsopoulos HM, Steinberg AD. Muscle involvement in systemic lupus erythematosus. JAMA 1981;246:766-8.
26. Medsger TA Jr. Systemic sclerosis (scleroderma): clinical aspects. In: Koopman WJ, editor. Arthritis and allied conditions. Baltimore: Williams and Wilkins; 1997. p. 1433-64.
27. Miller FW. Inflammatory myopathies: polymyositis, dermatomyositis and related conditions. In: Koopman WJ, editor. Arthritis and allied conditions. Baltimore: Williams and Wilkins; 1997. p. 1407-31.
28. Brand CA, Rowley MJ, Tait BD, Muirden KD, Whittingham SF. Coexistent rheumatoid arthritis and systemic lupus erythematosus: clinical, serological, and phenotypic features. Ann Rheum Dis 1992;51:173-6.
29. Graninger WB, Hassfeld W, Pesau BB, Machold KP, Zielinski CC, Smolen JS. Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis. J Rheumatol 1991;18:1621-2.
30. Horiki T, Moriuchi J, Takaya M, Uchiyama M, Hoshina Y, Inada K, et al. The coexistence of systemic sclerosis and rheumatoid arthritis in five patients: clinical and immunogenetic features suggest a distinct entity. Arthritis Rheum 1996;39:152-6.
31. Talal N, Moutsopoulos HM, Kassan SS, editors. Sjögren's syndrome: clinical and immunologic aspects. New York: Springer Verlag; 1987.
32. Graninger WB, Steinberg AD, Meron G, Smolen JS. Interstitial nephritis in patients with systemic lupus erythematosus: a manifestation of concomitant Sjögren's syndrome? Clin Exp Rheumatol 1991;9:41-5.
33. Gendi NST, Welsh KI, van Venrooij WJ, Vancheeswaran R, Gilroy J, Black CM. HLA type as a predictor of mixed connective tissue disease differentiation: ten-year clinical and immunogenetic followup of 46 patients. Arthritis Rheum 1995;38:259-66.
34. Sharp GC. Diagnostic criteria for classification of MCTD. In: Kasukawa R, Sharp GC, editors. Mixed connective tissue diseases and antinuclear antibodies. Amsterdam: Elsevier; 1987. p. 23-32.
35. Alarcon-Segovia D, Villareal M. Classification and diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp GC, editors. Mixed connective tissue diseases and antinuclear antibodies. Amsterdam: Elsevier; 1987. p. 33-40.
36. Kasukawa R, Tojo T, Miyawaki S. Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: Kasukawa R, Sharp GC, editors. Mixed connective tissue diseases and antinuclear antibodies. Amsterdam: Elsevier; 1987. p. 41-7.
37. Kahn MF, Appelboom T. Syndrome de Sharp. In: Kahn MF, Peltier AP, Meyer O, Piette JC, editors. Les maladies systémiques. 3rd ed. Paris: Flammarion; 1991. p. 545-56.
38. Amigues J-M, Cantagrel A, Abbal M, Mazieres B, and the Autoimmunity Group of the Hospitals of Toulouse. Comparative study of 4 diagnosis criteria sets for mixed connective tissue disease in patients with anti-RNP antibodies. J Rheumatol 1996; 23:2055-62.
39. Hassfeld W, Steiner G, Studnicka-Benke A, Skriner K, Graninger W, Fischer I, et al. Autoimmune response to the spliceosome: an immunologic link between rheumatoid arthritis, mixed connective tissue disease, and systemic lupus erythematosus. Arthritis Rheum 1995;38:777-85.
40. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
41. Lazaro MA, Maldonado Cocco JA, Catoggio LJ, Babini SM, Messina OD, Morteo OG. Clinical and serologic characteristics of patients with overlap syndromes: is mixed connective tissue disease a distinct clinical entity? Am Med 1989;68:58-65.
42. Grant KD, Adams LE, Hess EV. Mixed connective tissue disease - a subset with sequential clinical and laboratory features. J Rheumatol 1981;8:587-98.
43. Lundberg I, Nyman U, Petterson I, Hedfors E. Clinical manifestations and anti-(U1)snRNP antibodies: a prospective study of 29 anti-RNP antibody positive patients. Br J Rheumatol 1992;31: 811-7.
44. Piirainen HI. Patients with arthritis and anti-U1-RNP antibodies: a 10-year follow up. Br J Rheumatol 1990;29:345-8.
45. Mattioli M, Reichlin M. Characterization of a soluble nuclear ribonucleoprotein antigen reactive with SLE sera. J Immunol 1971;107:1281-90.
46. Reichlin M, Mattioli M. Correlation of a precipitin reaction to an RNA protein antigen and a low prevalence of nephritis in patients with systemic lupus erythematosus. N Engl J Med 1972;286:1194-5.
47. Tan EM, Kunkel HG. Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. J Immunol 1966;96:464-71.
48. Klein Gunnewiek JMT, van de Putte LBA, van Venrooij WJ. The U1 sn RNP complex: an autoantigen in connective tissue diseases. An update. Clin Exp Rheumatol 1997;15:549-60.
49. Lührmann RL, Kastner B, Bach M. Structure of spliceosomal RNPs and their role in pre-mRNA splicing. Biochim Biophys Acta 1990;1087:265-92.
50. Sharp PA. Split genes and RNA splicing. Cell 1994;77:805-15.
51. Nyman U, Lundberg I, Hedfors E, Pettersson I. Recombinant 70-kD protein used for determination of autoantigenic epitopes recognized by anti-RNP sera. Clin Exp Immunol 1990;81:52-8.
52. Habets WJ, de Rooij DJ, Hoet RM, van de Putte LBA, van Venrooij WJ. Quantitation of anti-RNP and anti-Sm antibodies in MCTD and SLE patients by immunoblotting. Clin Exp Immunol 1985;59:457-65.
53. Reichlin M, van Venrooij WJ. Autoantibodies to the URNP particles: relationship to clinical diagnosis and nephritis. Clin Exp Immunol 1991;83:286-90.
54. Smolen JS, Morimoto C, Steinberg AD, Wolf A, Schlossman SF, Steinberg RT, et al. Systemic lupus erythematosus: delineation of subpopulations by clinical, serologic and T cell subset analysis. Am J Med Sci 1985;289:139-49.
55. Vlachoyiannopoulos PG, Guilis A, Tzioufas G, Moutsopoulos HM. Predominance of IgM anti-U1RNP antibodies in patients with systemic lupus erythematosus. Br J Rheumatol 1996;35:534-41.
56. Barakat S, Briand JP, Abuaf N, van Regenmortel MH, Muller S. Mapping of epitopes on U1 snRNP polypeptide A with synthetic peptides and autoimmune sera. Clin Exp Immunol 1991;86:71-8.
57. Van Venrooij WJ, van Gelder CWG. B cell epitopes on nuclear autoantigens: what can they tell us? Arthritis Rheum 1994;37: 608-16.
58. Dreyfuss G, Matunis MJ, Pinol-Roma S, Burd CG. hnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem 1993;62:289-321.
59. Fritzler MJ, Ali R, Tan EM. Antibodies from patients with mixed connective tissue disease react with heterogeneous nuclear ribonucleoprotein or ribonucleic acid of the nuclear matrix. J Immunol 1984;132:1216-22.
60. Gelpi C, Rodriguez-Sanchez JL, Hardin JA. Purification of hnRNP from HeLa cells with a monoclonal antibody and its application in ELISA: detection of autoantibodies. Clin Exp Immunol 1988;71:281-8.
61. Astaldi-Ricotti GCB, Bestagno M, Cerini A, Negri R, Caporali R, Cobianchi F, et al. Antibodies to hnRNP core protein A1 in connective tissue diseases. J Cell Biochem 1989;40:1-5.
62. Steiner G, Hartmuth K, Skriner K, Maurer-Fogy I, Sinski A, Thalmann E, et al. Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. J Clin Invest 1992;90:1061-6.
63. Meyer O, Tauxe F, Fabregas D, Gabay C, Goycochea M, Haim T. et al. Anti-RA33 antinuclear autoantibody in rheumatoid arthritis and mixed connective tissue disease: a comparison with antikeratin and antiperinuclear antibodies. Clin Exp Rheumatol 1993;11:473-8.
64. Steiner G, Skriner K, Smolen JS. Autoantibodies to the A/B proteins of the heterogeneous nuclear ribonucleoprotein complex: novel tools for the diagnosis of rheumatic diseases. Int Arch Allergy Immunol 1996;111:314-9.
65. Burd CG, Swanson MS, Görlach M, Dreyfuss G. Primary structures of the heterogeneous nuclear ribonucleoprotein A2, B1 and C2 proteins: a diversity of RNA binding proteins is generated by small peptide inserts. Proc Natl Acad Sci U S A 1989;86:9788-92.
66. Skriner K, Sommergruber WH, Tremmel V, Fischer I, Barta A, Smolen JS, et al. Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex: differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus and mixed connective tissue disease. J Clin Invest 1997;100:127-35.
67. Tan EM, Muro Y, Pollard KM. Autoantibody-defined epitopes on nuclear antigens are conserved, conformation-dependent and active site regions. Clin Exp Rheumatol 1994;12 Suppl 1:27-31.
68. Von Mühlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995;24: 323-58.
69. Fatenajad S, Mamula MJ, Craft J. Role of intermolecular/ intrastructural B and T-cell determinants in the diversification of autoantibodies to ribonucleoprotein particles. Proc Natl Acad Sci USA 1993;90:12010-4.
70. James JA, Gross T, Scofield RH, Harley JB. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B′-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J Exp Med 1995;181:453-61.
71. Deutscher SL, Keene JD. A sequence-specific conformational epitope on U1 RNA is recognized by a unique autoantibody. Proc Natl Acad Sci U S A 1988;85:3299-304.
72. Van Venrooij WJ, Hoet R, Castrop J, Hageman B, Mattaj IW, van de Putte LB. Anti-(U1) small nuclear RNA antibodies in anti-small nuclear ribonucleoprotein sera from patients with connective tissue diseases. J Clin Invest 1990;86:2154-60.
73. Hoet RM, Koornneef I, de Rooij DJ, van de Putte LB, van Venrooij WJ. Changes in anti-U1 RNA antibody levels correlate with disease activity in patients with systemic lupus erythematosus overlap syndrome. Arthritis Rheum 1992;35:1202-10.
74. Hoffman RW, Sharp GC, Deutscher SL. Analysis of anti-U1 RNA antibodies in patients with connective tissue disease: asso3 ciation with HLA and clinical manifestations of disease. Arthritis Rheum 1995;38:1837-44.
75. O'Brien RM, Cram DS, Coppel RL, Harrison LC. T-cell epitopes on the 7OkDa protein of the (U1)RNP complex in autoimmune rheumatologic disorders. J Autoimmun 1993;3:747-57.
76. Okubo M, Yamamoto K, Kato T, Matsuura N, Nishimaki T, Kasukawa K, et al. Detection and epitope analysis of autoantigen-reactive T cells to the U1-small nuclear ribonucleoprotein A protein in autoimmune disease patients. J Immunol 1993;151:1108-15.
77. Hoffman RW, Takeda Y, Sharp GC, Lee DR, Hill DL, Kaneoka H, et al. Human T cell clones reactive against U-small nuclear ribonucleoprotein autoantigens from connective tissue disease patients and healthy individuals. J Immunol 1993;151:6460-9.
78. Fenning S, Wolff-Vorbeck G, Hackl W, Krawinkel U, Lührmann R, Northemann W, et al. T cell lines recognizing the 70kD protein of U1 small nuclear ribonucleoprotein (U1-snRNP). Clin Exp Immunol 1995;101:408-13.
79. Holyst M-M, Hill DL, Hoch SO, Hoffman RW. Analysis of human T cell and B cell responses against U small nuclear ribonucleoprotein 70-kd, B, and D polypeptides among patients with systemic lupus erythematosus and mixed connective tissue disease. Arthritis Rheum 1997;40:1493-503.
80. Reinertsen JL, Klippel JH, Johnson AH, Decker JL, Steinberg AD, Mann DL. B lymphocyte alloantigens associated with systemic lupus erythematosus. N Engl J Med 1978;299:515-8.
81. Scherak O, Smolen JS, Mayr WR. HLA-DRw3 and systemic lupus erythematosus. Arthritis Rheum 1980;23:954-7.
82. Reveille JD. Molecular genetics of systemic sclerosis. Curr Opin Rheumatol 1993;5:753-9.
83. Vargas Alarcon G, Granados J, Ibanez de Kasep G, Alcocer Varela J, Alarcon Segovia D. Association of HLA-DR5 (DR11) with systemic sclerosis (scleroderma) in Mexican patients. Clin Exp Rheumatol 1995;13:11-6.
84. Miller FW. Humoral immunity and immunogenetics in the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1991;3:902-10.
85. Stastny P. Association of B cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978;298:869-71.
86. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30:1205-13.
87. Black CM, Maddison PJ, Welsh KI, Bernstein R, Woodrow JC, Pereira RS. HLA and immunoglobulin allotypes in mixed connective tissue disease. Arthritis Rheum 1988;31:131-4.
88. Ruuska P, Hameenkorpi R, Forsberg S, Julkunen H, Makitalo R, Ilonen J, et al. Differences in HLA antigens between patients with mixed connective tissue disease and systemic lupus erythematosus. Ann Rheum Dis 1992;51:52-5.
89. Kaneoka H, Hsu K-C. Takeda Y, Sharp GC, Hoffman RW. Molecular genetic analysis of HLA-DR and HLA-DQ genes among anti-U1-70-kd autoantibody positive connective tissue disease patients. Arthritis Rheum 1992;35:83-94.
90. Sontheimer RD, Maddison PJ, Reichlin M, Jordan RE, Stastny P, Gilliam JN. Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med 1982;97:664-71.
91. Briggs DC, Vaughan RW, Welsh KI, Myers A, DuBois RM, Black CM. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991;338:661-2.
92. Smolen JS, Klippel JH, Penner E, Reichlin M, Steinberg AD, Chused TM, et al. HLA-DR antigens in systemic lupus erythematosus: association with specificity of autoantibody responses to nuclear antigens. Ann Rheum Dis 1987;46:457-62.
93. Bell DA, Maddison PJ. Serologic subsets in systemic lupus erythematosus: an examination of autoantibodies in relationship to clinical features of disease and HLA antigens. Arthritis Rheum 1980;23:1268-73.
94. Olsen ML, Arnett FC, Reveille JD. Contrasting molecular patterns of MHC class II alleles associated with the anti-Sm and anti-RNP precipitin autoantibodies in systemic lupus erythematosus. Arthritis Rheum 1993;36:94-104.
95. Hoffman RW, Rettenmaier LJ, Takeda Y, Hewett JE, Pettersson I, Nyman U, et al. Human autoantibodies against the 70-kd polypeptide of U1 small nuclear RNP are associated with HLA-DR4 among connective tissue disease patients. Arthritis Rheum 1990;33:666-73.
96. Brown JH, Jardetzlu T, Saper MA, Samraoui B, Bjorkman PJ, Wiley DC. A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules. Nature 1988;332: 845-50.
97. Ikaheimo IL, Tiilikainen AS, Hameenokorpi R, Silvennoinen-Kassinen SH. Different distribution of T cell receptor beta-chain haplotypes in mixed connective tissue disease and systemic lupus erythematosus. Ann Med 1994;26:129-32.
98. McNeilage LJ, Macmillan EM, Whittingham SF. Mapping of epitopes on the La(SS-B) autoantigen of primary Sjögren's syndrome: identification of a cross-reactive epitope. J Immunol 1990;145:3829-35.
99. Craft J, Fatenejad S. Self antigens and epitope spreading in systemic autoimmunity. Arthritis Rheum 1997;40:1374-82.
100. Suenaga R, Munoz PA, Bright SW, Abdou NI. Spontaneous shift of anti-DNA antibody idiotypes in systemic lupus erythematosus. J Immunol 1988;140:3508-14.